Le Lézard
Classified in: Health, Business
Subjects: TNM, ATY

Harwood Feffer LLP Announces Investigation of Health Net, Inc.



NEW YORK, July 2, 2015 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Health Net, Inc. ("Health Net" or the "Company") (NYSE: HNT) concerning the proposed acquisition of the Company by Centene Corporation ("Centene") (NYSE: CNC).

Harwood Feffer LLP.

Under the terms of the offer, Centene would acquire Health Net in a transaction valued at approximately $6.8 billion.  Pursuant to the deal, Health Net stockholders would receive 0.622 shares of Centene common stock and $28.25 in cash for each share of Health Net, a combined value of approximately $75.55

Our investigation concerns whether the Health Net board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders. 

If you own Health Net shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com 
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP


These press releases may also interest you

at 03:00
Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodytm (CPAB) based oncology therapeutics announces that it has been awarded a ?0.5 million grant (approximately USD$0.6 million) from the...

at 01:30
reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND's ReS39 therapeutic program of diabetes. This program holds also promise for NASH and the metabolic syndrome.        (Logo:...

at 00:01
Over the last 10 years, the rate of deceased organ donation has increased 42%, according to the latest numbers released by the Canadian Institute for Health Information (CIHI) and Canadian Blood Services. Close to 2,900 lifesaving transplants were...

at 00:01
By almost every measure, Ontario students in grades 7 through 12 are drinking, smoking, and using drugs at the lowest rates since the Ontario Student Drug Use and Health Survey (OSDUHS) began in 1977. This is according to new numbers released today...

13 déc 2017
Half of all individuals in Canada born with cystic fibrosis will not live past around 50 years of age. Emily Lyons ? successful serial entrepreneur and CEO of multiple Toronto-based companies ? experienced firsthand the reality of this sobering...

13 déc 2017
A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the...




News published on 2 july 2015 at 13:20 and distributed by: